EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis

Hung N Nguyen, Yunju Jeong, Yunhye Kim, Mari Kamiya, Yaunghyun Kim, Humra Athar, Peter J Castaldi, Craig P Hersh, Jaivardhan A Menon, Jessie Wong, Ian Chan, William M Oldham und 13 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2401899121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Hung N Nguyen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA 02115. Hauptthemen laut MEDLINE: Leukemia Inhibitory Factor, Idiopathic Pulmonary Fibrosis, Transforming Growth Factor beta1, Fibroblasts. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, HHS | NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrosis drives end-organ damage in many diseases. However, clinical trials targeting individual upstream activators of fibroblasts, such as TGFβ, have largely failed. Here, we target the leukemia inhibitory factor receptor (LIFR) as an “autocrine master amplifier” of multiple upstream activators of lung fibroblasts. In idiopathic pulmonary fibrosis (IPF), the most common fibrotic lung disease, we found that lung myofibroblasts had high LIF expression, and the fibroblasts in fibroblastic foci coexpressed LIF and LIFR. In IPF, fibroblastic foci are the “leading edge” of fibrosis and a key site of disease pathogenesis. TGFβ1, one of the principal drivers of fibrosis, up-regulated LIF expression in IPF fibroblasts. We found that TGFβ1, IL-4, and IL-13 stimulations of fibroblasts require the LIF-LIFR axis to evoke a strong fibrogenic effector response in fibroblasts. In vitro antibody blockade of LIFR on IPF lung fibroblasts reduced the induction of profibrotic genes after TGFβ1 stimulation. Silencing LIF and LIFR reduced profibrotic fibroblast activation following TGFβ1, IL-4, and IL-13 stimulations. We also demonstrated that LIFR amplified profibrotic stimuli in precision-cut lung slices from IPF patients. These LIFR signals were transduced via JAK2, and STAT1 in IPF lung fibroblasts. Together, we find that LIFR drives an autocrine circuit that amplifies and sustains pathogenic activation of IPF fibroblasts. Targeting a single, downstream master amplifier on fibroblasts, like LIFR, is an alternative therapeutic strategy that simultaneously attenuates the profibrotic effects of multiple upstream stimuli.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia Inhibitory FactorIdiopathic Pulmonary FibrosisTransforming Growth Factor beta1FibroblastsInterleukin-13LungHumansInterleukin-4Leukemia Inhibitory Factor Receptor alpha SubunitSignal TransductionJanus Kinase 2Myofibroblasts

Stichwörter der Autor:innen

autocrine communicationfibroblastsleukemia inhibitory factorpulmonary fibrosisreceptors OSM-LIF

Substanzen

Leukemia Inhibitory FactorTransforming Growth Factor beta1LIF protein, humanInterleukin-13Interleukin-4LIFR protein, humanLeukemia Inhibitory Factor Receptor alpha SubunitJanus Kinase 2TGFB1 protein, humanIL4 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA 02115.
  • Harvard Medical School, Boston, MA 02115.
  • Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115.
  • Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Department of Pediatrics, Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA 02115.
  • Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA 02115.

ORCID-Profile: Edy Y Kim

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • HHS | NIH
  • HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • NIAMS NIH HHS
  • Bell Family Fund
  • American Lung Association (ALA)

Zitieren

APA

Nguyen, H. N., Jeong, Y., Kim, Y., Kamiya, M., Kim, Y., Athar, H., Castaldi, P. J., Hersh, C. P., Menon, J. A., Wong, J., Chan, I., Oldham, W. M., Padera, R. F., Sharma, N. S., Sholl, L. M., Vivero, M., Watts, G. F. M., Knipe, R. S., Black, K. E., …, & Brenner, M. B. (2024). Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2401899121

Vancouver

Nguyen HN, Jeong Y, Kim Y, Kamiya M, Kim Y, Athar H, et al. Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2401899121

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Hung N and Jeong, Yunju and Kim, Yunhye and Kamiya, Mari and Kim, Yaunghyun and Athar, Humra and Castaldi, Peter J and Hersh, Craig P and Menon, Jaivardhan A and Wong, Jessie and Chan, Ian and Oldham, William M and Padera, Robert F and Sharma, Nirmal S and Sholl, Lynette M and Vivero, Marina and Watts, Gerald F M and Knipe, Rachel S and Black, Katharine E and Hariri, Lida P and Yun, Jeong H and Merriam, Louis T and Yuan, Ke and Kim, Edy Y and Brenner, Michael B},
  title = {Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2401899121}
}
Kostenlos starten →